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BACKGROUND: Elastin peptides possess several biological activities and in vitro data suggest they could be involved in the early phase
of melanoma growth.
METHODS: Using diverse in vitro and in vivo techniques (cell proliferation, invasion and migration assays, zymography, western blots,
collagen degradation assay, reverse transcription PCR, melanoma allographs and immunohistochemistry), we analysed the effect of
elastin-derived peptides (EDPs) on B16F1 melanoma growth and invasion, as well as on the proteolytic systems involved.
RESULTS: We found that EDPs dramatically promote in vivo tumour development of B16F1 melanoma, as well as their in vitro migration
and invasion. The inhibition of serine proteases and matrix metalloproteinases (MMPs) activities, by aprotinin and galardin,
respectively, demonstrated that these enzymes were involved in these processes. However, we found that EDPs did not increase
urokinase-type plasminogen activator, tissue-type plasminogen activator or MMP-2 expression and/or activation, neither in vitro nor
in vivo. Nevertheless, we observed a strong increase of pro-MMP-9 secretion in EDPs-treated tumours and, more importantly, an
increase in the expression and activation of the murine counterpart of MMP-1, named murine collagenase-A (Mcol-A). Moreover, we
show that plasminogen system inhibition decreases collagen degradation by this enzyme. Finally, the use of a specific blocking
antibody against Mcol-A abolished EDP-induced B16F1 invasion in vitro, showing that this MMP was directly involved in this process.
CONCLUSION: Our data show that in vivo, EDPs are involved in melanoma growth and invasion and reinforced the concept of elastin
fragmentation as a predictive factor.
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Extracellular matrix (ECM) degradation is a prerequisite for
cancer progression. Beside the fact that its degradation is essential
to allow cell migration through its three-dimensional architecture,
the generated ECM fragments are not inactive. Indeed, ECM
proteolysis leads to the release of matrikines, matrix fragments
that display proper biological activities from their original matrix
counterparts (Hornebeck et al, 2002).
Elastin constitutes one of the ECM proteins responsible for the
elasticity of tissues (Kielty et al, 2002). Protease-driven elastin
degradation can occur during physiopathological processes such
as cancer progression (Hornebeck et al, 2005). The generated
bioactive elastin-derived peptides (EDPs) are thought to contribute
to tumour progression (Duca et al, 2004).
Several in vitro studies (Yusa et al, 1989; Timar et al, 1991;
Svitkina and Parsons, 1993; Ntayi et al, 2004) suggest that
EDPs could promote cutaneous melanoma growth and invasion.
For instance, it has been shown that the incidence of metastases
increased as melanoma reached the subepidermal and dermal
layers, suggesting that elastin degradation could facilitate
melanoma progression (Breslow, 1970). In addition, intense
elastin fragmentation was detected at the in vivo invasive
front of melanoma (Ntayi et al, 2004). It has moreover been
shown that EDPs amplify melanoma invasion through their
binding to the elastin-binding protein, avb3 and galectin-3
receptors (Pocza et al, 2008). However, no in vivo studies were
carried out to determine the influence of EDPs on melanoma
growth and invasion.
Cutaneous melanoma is characterised by its strong ability to
form metastases (Hofmann et al, 2005). If melanoma is diagnosed
early, it can be cured by surgical resection. On the other
hand, metastatic malignant melanoma is refractory to existing
therapies and has a very poor prognosis. New treatment
strategies are consequently urgently needed and the identi-
fication of new early predictive marker of melanoma metastatic
potential is of crucial interest to handle the pathology as fast
as possible.
Two classes of proteinases have been shown to be involved in
melanoma invasion: the matrix metalloproteinases (MMPs) and
the plasminogen activation system (Pasco et al, 2004a).
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in physiological and physiopathological conditions. Human
melanoma invasion involved MMP-1, MMP-2, MMP-9 and
MT1-MMP (Walker and Woolley, 1999; Hofmann et al, 2005).
Nevertheless, and on the contrary of the others precited MMPs,
MMP-1 was initially thought to be absent from murine tissues.
However, murine collagenase-A (Mcol-A) was recently discovered.
It has a role similar to human MMP-1, and is able to degrade
fibrillar collagens (Balbin et al, 2001). The MMPs are synthesised
as inactive zymogens and their proteolytic activation occurs in the
extracellular space by others MMPs or by plasmin.
The plasminogen/plasmin system has largely been documented
and is involved in melanoma invasion (de Vries et al, 1996;
Andreasen et al, 1997, 2000). The cleavage of plasminogen involves
two activators named urokinase-type plasminogen activator (uPA)
and tissue-type plasminogen activator (tPA).
We show, for the first time, that EDPs strongly enhance murine
melanoma development in vivo. This important finding point out
that elastin degradation, which occurs during melanoma develop-
ment, is one of the events that could drive tumour growth.
Moreover, using several biochemical methods, we demonstrate
that EDPs specifically enhance in vitro and in vivo Mcol-A
expression and that this enzyme could be responsible for
EDP-stimulated melanoma invasion.
In conclusion, our results show that elastin degradation
products are important modulators of in vivo melanoma growth
and invasion through Mcol-A (MMP-1) expression. Moreover, our
work demonstrates that elastin degradation could be an important
predictive factor of evolution in melanoma.
MATERIALS AND METHODS
Reagents and antibodies
Elastin-derived peptides (k-elastin, also noted as EDPs) were
prepared as previously described (Debelle et al, 1995; Brassart
et al, 2001). Briefly, insoluble elastin was prepared from bovine
ligamentum nuchae by hot alkali treatment. Its purity was assessed
by comparing its amino acid composition to that predicted from
the elastin gene product. Soluble elastin peptides were obtained
from insoluble elastin by organo-alkaline hydrolysis. This was
achieved using 1 M KOH in 80% aqueous ethanol. The obtained
mixture of elastin peptides is termed k-elastin and exhibits the
same biological and physical properties than elastin hydrolysates
(Brassart et al, 2001). Bovine serum albumin (BSA), gelatin,
plasminogen and aprotinin, a commonly used inhibitor of the
plasminogen system (Ramont et al, 2003), were purchased from
Sigma (Saint-Quentin Fallavier, France). All reagents for cell
culture were from Gibco BRL (Invitrogen, Cergy Pontoise, France).
Galardin, a synthetic broad-spectrum MMP inhibitor (Agren
et al, 2001), the anti-human-MMP1 (Ab-3) used for western blot
analyses and the anti-human-MMP-1 (Ab-6) used in blocking
experiments (Brennan et al, 2003) were from Calbiochem
(distributed by VWR Int., Strasbourg, France). All these antibodies
were checked for their mouse cross-reactivity. The anti-monocyte/
macrophage (MoMa-2) was from BMA Biomedicals (Rheinstrasse,
Switzerland). All other reagents were from Sigma.
Cell culture and treatments
B16F1 cells, a lung metastatic subline of murine B16 melanoma,
were cultured in RPMI 1640 medium supplemented with 10% heat-
inactivated fetal bovine serum (FBS) in 25cm
2 flasks at 371Ci na
humidified atmosphere of 5% CO2/95% air. For the evaluation of
EDPs effects on proteases expression and activation, cells were
seeded onto 24-well plates and subconfluent cultures were washed
twice in phosphate-buffered saline to eliminate residual FBS and
then incubated or not with 50mgml
–1 EDPs for 48h. After the
incubation period, the culture media were harvested, centrifuged
for 10min at 500g to eliminate cellular debris and then submitted
to western blot or zymography analyses. In all experiments, cell
viability was 495% when cell culture supernatants were collected
as evaluated by MTT assay. For cell proliferation assay, B16F1 were
seeded in 96-well plates in complete medium with or without EDPs
for 72h. Cell proliferation was determined by counting cells with
a Malassez cell.
Migration assay
B16F1 cells (75.10
5) have been seeded in 12-well plates in complete
medium. After 48h, cell media were eliminated, and a homo-
geneous wound was created in each well by scraping cells with a tip
followed by two washings with RPMI 1640 in order to eliminate
dead cells and cellular debris. Cells were stimulated or not for
48h with 50mgml
–1 EDPs and cell migration was evaluated by
videomicroscopy (Axiovert 200M, Zeiss, Heidelberg, Germany).
In vitro invasion assays
The invasive potential of tumour cells was examined using
modified Boyden chambers, 6.5mm diameter and 8mm pore
(Transwell, Costar, Brumath, France) according to the manufac-
turer’s instructions. Briefly, cells were suspended in serum-free
RPMI containing 0.2% BSA, and 100ml of the cell suspension
(50 10
3 cells) was seeded onto the upper compartment of the
Transwell coated with Matrigel (40mg per well). In the lower
compartment, 800ml RPMI containing 10% FBS and 2% of BSA
was used as chemoattractant. The cells were incubated with or
without aprotinin (100mgml
–1), galardin (10
 9M), both or with
a monoclonal anti-MMP-1-blocking antibody (10mgml
–1) and
stimulated or not with EDPs (50mgml
–1). Transwells were
incubated at 371C under 5% CO2/95% air atmosphere for 40h
and cells were then fixed with methanol. Non-invading cells
remaining on the upper side of the filter were scrapped off.
Invading cells on the lower side of the filter were then stained with
crystal violet for 15min, microscopically observed and counted in
five fields at  200 magnification. The invasive activity of cancer
cells was expressed as the mean number of cells that have crossed
Matrigel.
Mice and tumours
Female C57Bl6 mice (average body weight: 18–20g) were
purchased from Harlan France (Gannat, France). Animals
were individually caged and given food and water ad libitum.
They were kept in a room with constant temperature and
humidity. All mice were acclimatised to laboratory conditions
for 1 week before starting the experiments. The experiments were
conducted according to the recommendations of the Centre
National de la Recherche Scientifique. Mice (five mice per group)
were injected subcutaneously with 2.5 10
5 B16F1 cells in 100mlo f
RPMI containing or not EDPs (100mg). The mice were reinjected at
tumour site with EDPs at day 7. Each tumour was measured
according to v¼1/2 A
2 B (A, smallest superficial diameter;
B, largest superficial diameter) (Pasco et al, 2004b).
Tumours and cell protein extraction
Tumours were surgically extracted at day 10 and homogenised in
Net Buffer (100mM Tris, pH 7.4, 300mM NaCl, 10mM EDTA, 2%
NP40). For cell extracts, cells were homogenised in lysis buffer
(Tris 10mM, pH 7.4, NaCl 150mM, 1% Triton X-100, EDTA 5mM)
containing protease inhibitors. Proteins were quantified using the
Bradford method, with BSA as a standard.
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Sections of 6mm from formalin-fixed, paraffin-embedded tumours
were used for immunohistochemical detection of monocyte/
macrophage and Mcol-A. The sections were deparaffinised,
rehydrated and treated with citrate buffer for antigen retrieval.
Endogenous peroxidase activity was blocked with incubation of
the slides in 3% H2O2 in phosphate-buffered saline for 10min.
Sections were preincubated for 30min with 1% BSA and incubated
overnight at 41C with a sheep anti-MMP-1 antibody (1/100) or
rat anti-monocyte/macrophage antibody (1/50) followed by an
incubation with the corresponding secondary antibody linked
to peroxidase treatment. Antibody binding was visualised with
diaminobenzidin, and then the slides were counterstained with
Methylene Green zinc chloride double salt (Sigma).
Western blot analysis
Protein of 20mg was subjected to SDS–polyacrylamide gel
electrophoresis and transferred onto nitrocellulose membranes.
Membranes were incubated in blocking buffer (5% non-fat dry
milk, 0.1% Tween 20 in 50mM Tris–HCl buffer, 150mM NaCl,
pH 7.5) for 1h at room temperature. They were thereafter
incubated overnight at 41C with the rabbit anti-MMP-1 (1/500)
primary antibody diluted in blocking buffer and then with the
corresponding peroxidase-conjugated secondary antibody for 1h
at room temperature. Immune complexes were visualised using
enhanced chemiluminescence.
Gelatin and gelatin plasminogen zymography
Gelatinases and plasminogen activators (PAs) expression from
conditioned media of B16F1 and tumour extracts (10mg proteins
per sample) were analysed using SDS–polyacrylamide gel electro-
phoresis containing 0.1% gelatin for gelatin zymography or 0.1%
of gelatin and 0.25Uml
–1 plasminogen for gelatin–plasminogen
zymography. After electrophoresis, the gels were soaked in 2.5%
(v/v) Triton X-100 solution for 1h to remove SDS. For gelatin
zymography, gels were then incubated in 50mM Tris–HCl (pH 7.6)
containing 5mM CaCl2 and 200mM NaCl overnight at 371C. For
gelatin–plasminogen zymography, gels were then incubated over-
night at 371C in 100mM glycine buffer, 5mM EDTA, pH 8.0. The
gels were then stained with 0.1% (w/v) G250 Coomassie brilliant
blue in 45% (v/v) methanol/10% (v/v) acetic acid. After 10min, the
gels were destained with 25% (v/v) methanol/10% acetic acid for
1h. The proteolytic activity was detected as clear bands on a blue
background of the Coomassie brilliant blue-stained gel.
Reverse transcription PCR
Total RNA was isolated after lysis of B16F1 cells. Following OD
assessment and gel analysis, 250ng total RNA was reverse
transcribed. The following cycling profile was used: 30s at 941C,
30s at 571C, 30s at 721C for 30 cycles. The PCR products were
analysed in 2% ethidium bromide-stained agarose gels. The
forward (F) and reverse (R) primer sequences for the different
PCR products and their size in base pairs (bp) were as follows:
Mcol-A F: 50-TTCATGCCAGAACCTGAGCTC-30,
Mcol-A R: 50-GGGAAGCCAAAGAAACTGTGG (110bp)-30;
b- Actin F: 50-GTGTGACGTGGACATCCGC-30,
b-Actin R: 50-CTGCATCCTGTCGGCAATG-30 (91bp).
Collagen degradation assay
The influence of Mcol-A expression following EDPs treatment
on collagen degradation was evaluated using DQ-collagen
(Invitrogen) following the manufacturer’s instructions. Briefly,
100ml from B16F1 conditioned media (48h) incubated or not with
EDPs (50mgml
–1) and/or aprotinin (100mgml
–1) were incubated
with reaction buffer (80ml) and 20ml of DQ-collagen (100mgml
–1)
for 4h. The degradation of DQ-collagen was evaluated by
fluorescence emission (lex¼495nm; lem¼515nm).
Densitometric analysis and statistical evaluation
Each band from polyacrylamide gels was quantified using Quantity
One software (Bio-Rad Laboratories, Marne-la-Valle ´e, France).
Each experiment was performed at least three times, from separate
sets of culture. Data were expressed as mean±s.e.m. Comparisons
were performed using Student’s t-test.
RESULTS
EDPs enhance melanoma growth in vivo and in vitro cell
proliferation
To determine the effect of EDPs on melanoma development,
control B16F1 cells or B16F1 preincubated for 30min in the
presence of EDPs (100mg) were subcutaneously injected into the
right side of syngenic C57Bl6 mice. Control and EDP-treated mice
were killed on day 10. Tumours were excised and measured.
Tumour mean volume was increased by at least three-fold
(Po0.05) in EDP-treated mice vs control (Figure 1A), showing
that EDPs strongly enhanced melanoma growth in vivo.T o
confirm that such an effect is directly mediated by the elastin
peptides, that is, that EDPs do not signal via other ECM
components, we evaluate their pro-proliferative abilities towards
B16F1 cells. The stimulation of melanoma cells with EDPs in the
presence of 10% FBS triggered cell proliferation at 72h in a dose-
dependent manner (Figure 1B). The optimal concentration is
reached since 50mgml
–1. It has to be emphasised that EDPs
present no effect on cell proliferation for FBS concentrations
inferior to 10%. These results consequently demonstrate that EDPs
directly enhanced melanoma growth.
EDPs increase B16F1 in vitro migration and invasion
B16F1 cells were tested for their ability to migrate following EDPs
stimulation in an in vitro system. Briefly, B16F1 were seeded on
plastic dishes then scrapped at the centre of the dish. The
migration of the cells was evaluated by videomicroscopy using
their ability to fill the gap. These experiments were performed
using 2.5% FBS, a concentration for which EDPs has no effect on
cell proliferation. We found that EDPs enhanced B16F1 migration
as the artificially created wound was more filled compared with
control (Figure 2A). B16F1 cells were then tested for their ability to
migrate through Matrigel-coated (40mg per well) membranes for
40h in the presence or absence of EDPs. The incubation of
melanoma cells with EDPs led to a significant increase in their
invasive properties (þ36%) comparatively to control cells
(Figure 2B). These results demonstrated that EDPs increased
melanoma cell invasion and showed that, in addition to trigger
in vivo growth, they enhance cell invasion. These results support
the detrimental role of EDPs in in vivo melanoma development.
Aprotinin decreases invasion of EDP-induced B16F1 cells
One of the proteolytic systems involved in melanoma invasion is
the PA system (de Vries et al, 1996; Andreasen et al, 1997, 2000). In
order to determine the contribution of PA in EDP-induced B16F1
melanoma invasion, the invasiveness of B16F1 or EDP-treated
B16F1 cells was assayed in vitro in the presence of aprotinin
(Ramont et al, 2003). As shown in Figure 2C, aprotinin inhibited
invasion of unstimulated or EDP-stimulated B16F1 cells. It is
however important to note that the increase in invasion observed
EDPs induce in vivo melanoma development
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demonstrating that the increase involved the plasminogen system.
To analyse the effects of EDPs on PAs uPA and tPA, we
performed gelatin plasminogen zymography from tumour lysates
and conditioned culture media. No increase in uPA nor tPA
expression was observed neither in vivo nor in vitro (Figure 2D).
Thus, we hypothesised that EDPs could enhance melanoma
invasion by inducing pro-MMPs expression, whose activation
could occur through the plasminogen activation system.
Galardin blocks EDP-stimulated B16F1 cell invasion by
blocking MMPs activity
The MMPs constitute the second major proteolytic system used
by melanoma cells to invade ECM (Hofmann et al, 2000).
The invasive properties of B16F1 and EDP-stimulated B16F1 cells
were assayed in vitro in the presence of galardin (Agren et al,
2001). Galardin decreased invasion of B16F1 cells stimulated or
not with EDPs (Figure 3A), suggesting that MMPs are required for
basal and EDP-induced B16F1 invasion. Importantly, co-treatment
of cells with galardin and aprotinin together (Figure 3A) gave
the same results than galardin alone, indicating that MMPs activity
is sufficient to mediate matrix degradation induced by EDPs.
Owing to the important role of gelatinases A and B in the
invasion process of melanoma (Hofmann et al, 2000; Seiki, 2002),
we investigated their expression and their activation in vitro
and in vivo. These analyses evidenced no variation in the
pattern of expression and activation of these MMPs (Figure 3B),
as well as for MT1-MMP (data not shown). Nevertheless, a high
expression of pro-MMP9 was observed in EDP-treated tumours
lysates.
Increase in pro-MMP-9 expression in EDP-treated
B16F1 tumours correlates with infiltration of
monocytes/macrophages
The results described above let us to hypothesise that EDP-treated
mice tumours contained more infiltrating monocytes/macrophages
than controls. Indeed, it has been shown in tumours that MMP-9
is mostly expressed by these cells (Foda and Zucker, 2001).
Therefore, we performed an immunolabelling of infiltrating
monocytes/macrophages in tumour sections by using an anti-
MoMa-2 antibody. Immunohistochemistry evidenced that infil-
trating cells were highly present in EDP-treated tumours
(Figure 3C).
EDPs treatment increases Mcol-A secretion and activation
through the plasminogen system
Collagenase-1 (MMP-1) has been shown to be important in
melanoma development (Walker and Woolley, 1999; Hofmann
et al, 2005) and could be activated by the plasminogen system
(Benbow et al, 1999). Additionally, it is known that EDPs strongly
induce MMP-1 expression (Brassart et al, 2001). Reverse
transcription PCR analysis (Figure 4A) demonstrated that EDPs
significantly enhanced the expression of Mcol-A, the murine
counterpart of MMP-1 (Balbin et al, 2001) comparatively to
control cells. At the protein level, we found that EDPs increase the
Mcol-A expression level but also its activation (Figure 4B).
Moreover, data obtained from immunohistochemistry labelling
confirmed these results by showing a strong increase of the
expression of Mcol-A in EDP-treated mice tumours compared with
control B16F1 tumours (Figure 4C).
In order to evaluate the consequence of this process on the
degradation of the ECM and the role of the plasminogen system
in Mcol-A activation, we measured the degradation of fuorigenic
DQ-collagen by B16F1-conditioned media (Figure 4D). We
show that EDPs drastically increased DQ-collagen degradation.
The presence of aprotinin blocked this process. EDPs consequently
trigger matrix degradation through collagen digestion and this
process is dependent on Mcol-A activation by the plasminogen
system.
An anti-MMP-1 antibody blocks the effects of EDPs on
melanoma invasion in vitro
In order to validate the involvement of Mcol-A in EDP-induced
melanoma invasion, B16F1 cells treated or not with EDPs were
preincubated with a specific blocking anti-MMP-1 antibody
(Brennan et al, 2003) (10mgml
–1) and the invasiveness was
assayed in vitro. As shown in Figure 4E, treatment of B16F1 and
EDP-treated B16F1 with this antibody significantly decreased their
invasive properties, reproducing the effect of galardin on B16F1
invasiveness after stimulation by EDPs. These results show that
Mcol-A has a central role in elastin peptide-driven melanoma
invasion.
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Figure 1 Elastin-derived peptides increase melanoma tumour growth
in vivo (A) and in vitro cell proliferation (B). (A) B16F1 or EDP-pretreated
B16F1 were subcutaneously injected to female syngenic C57Bl6 mice
(2.5 10
5 cells per mouse) as described in the Materials and Methods
section. Mice were killed at day 10. Tumour sizes were measured and
statistical significance was calculated according to the Student’s t-test. Data
represent the average of five mice. A second experiment conducted under
the same conditions gave identical results. *Significantly different at Po0.05.
(B) B16F1 were seeded in 96-well plates in complete medium with or
without EDPs for 72h. Cell proliferation was determined by counting cells
with a Malassez cell. Data are expressed as mean±s.e.m. values from three
independent experiments, each performed in triplicate. **Significantly
different at Po0.01.
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Figure 2 Elastin-derived peptides stimulate B16F1 migration (A) and invasion (B). Invasion involves the plasminogen system (C) without inducing tPA or
uPA (D). (A) B16F1 cells have been seeded in 12-well plates and a homogeneous wound was created in each well by scraping cells with a tip. Cells were
stimulated or not for 48h with 50mgml
–1 EDPs and cell migration was evaluated by videomicroscopy. (B) Cellular invasive potential was assayed using
Transwell coated with Matrigel (40mg per well). In total, 50 10
3 cells in 100ml of RPMI 1640 with or without EDPs (50mgml
–1) were deposited into the
upper chamber. The lower chamber contained 10% FBS and 2% of BSA. Incubation was for 40h. Data are expressed as mean±s.e.m. values from three
independent experiments, each performed in triplicate. **Significantly different at Po0.01. (C) is same as (B) except for the presence or not of aprotinin
(100mgml
–1). **Significantly different at Po0.01. NS¼nonsignificantly different. (D) Upper panel: Gelatin plasminogen zymography was performed as
described in the Materials and Methods section. The gels presented are representative of several in vitro (n¼3) and in vivo (n¼5) experiments. Lower panel:
Quantification of in vitro and in vivo expressions of tPA and uPA was carried out using densitometry and calculating using Quantity One Software.
C¼untreated control; EDPs¼EDP-treated cells or tumours; NS¼nonsignificantly different.
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The tumour microenvironment has an important role in cancer
progression and in vitro assays have shown that matrix-derived
peptides could be the important factors (Hornebeck et al, 2002).
For instance, EDPs have been suggested to actively participate to
melanoma growth and invasion. Nevertheless, no in vivo studies
had been conducted to address this point.
We show for the first time, that EDPs are crucial modulators
of melanoma growth in vivo. Moreover, we further suggest that
Mcol-A could have a central role in EDP-enhanced tumour invasion.
Using a subcutaneous system of B16F1 implantation, we show
that EDPs increase B16F1 tumour development 10 days post-
challenge by three folds. We also demonstrated that EDPs induced
in vitro proliferation of melanoma cells, demonstrating that they
directly trigger this process in vivo. Such an effect has already been
reported for several cell types (Duca et al, 2004). Our results
comfort these data. Intense fragmentation of elastin has been
observed at the invasive front of melanoma and in vitro studies
suggested that EDPs could participate to such a process in vivo by
inducing proteolytic cascades (Yusa et al, 1989; Timar et al, 1991;
Svitkina and Parsons, 1993; Ntayi et al, 2004). However, no in vivo
studies were previously carried out to confirm this hypothesis. We
then analysed EDPs effect on melanoma migration and invasion
using well-established in vitro migration and invasion systems. We
have shown that EDPs increase the melanoma migration and also,
by 36%, the B16F1 invasion. Altogether, these results demonstrate
that EDPs enhanced melanoma growth and invasion both in vitro
and in vivo.
Two main proteolytic cascades are involved in melanoma
development, the plasminogen activation system and the MMPs
family (Pasco et al, 2004a). We found that aprotinin blocked
EDP-enhanced B16F1 invasion, suggesting a requirement of the
plasminogen activation system. Surprisingly, we observed that this
treatment did not induce neither tPA nor uPA expression in vitro
nor in vivo. Moreover, we have shown that EDPs treatment does
not modulate plasminogen activation (data not shown). This is in
contrast with our results using aprotinin suggesting that this
system is required in EDP-induced invasion. Therefore, even if tPA
or uPA expressions are not induced, their basal activity level could
be required to induce cell invasion by activating a novel pool of
MMPs expressed following EDPs treatment. The analysis of the
influence of galardin on EDPs-stimulated melanoma invasion
demonstrates a blockade of the basal invasion of B16F1 cells as
well as that induced by EDPs treatment. These results demonstrate
a role of MMPs in the EDP-triggered invasion. Moreover, the fact
that the use of aprotinin with galardin exhibited the same
effects than galardin alone supports our previous hypothesis that
MMPs constitute the central proteolytic system involved in
EDP-enhanced melanoma invasion.
EDPs were shown to induce the expression of several MMPs in
various tumour cell types (Duca et al, 2004). Among these
proteases, MMP-2 has been largely involved in melanoma invasion
(Ray and Stetler-Stevenson, 1995; Vaisanen et al, 1996) and a
correlation between its expression and melanoma prognosis has
been established (Vaisanen et al, 1998). Although conflicting data
have been reported concerning the role of MMP-9 in melanoma
invasion, several studies have shown that this MMP could be
involved in the progression of this disease (Itoh et al, 1999;
MacDougall et al, 1999). Although EDPs treatment had no effect on
MMP-2 expression both in vitro and in vivo, a high increase in
pro-MMP-9 expression in vivo was observed. However, as only the
pro-form of this enzyme can be detected, its participation in
matrix degradation could be excluded. MMP-9 can be produced by
cancer or stromal cells but is mostly secreted by macrophages
(Foda and Zucker, 2001). Moreover, previous in vitro studies
showed that EDPs are chemotactic for inflammatory cells (Duca
et al, 2004).
It was therefore possible that EDP-treated tumours contained
more monocytes/macrophages than control tumours, which would
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sexplain the observed increase of pro-MMP-9 secretion. Immuno-
histochemistry experiments showed that EDP-treated tumours
effectively exhibited a drastic increase in infiltrating monocytes/
macrophages, confirming our hypothesis.
Many studies underline that MT1-MMP exhibits intrinsic
matrix-degrading activities on various matrix proteins and
promotes tumour invasion and melanoma growth (d’Ortho et al,
1997; Deryugina et al, 2002; Iida et al, 2004). We checked the
influence of EDPs on MT1-MMP expression and no enhancement
in MT1-MMP expression or activation, both in vitro and in vivo,
was observed (data not shown).
Finally, MMP-1 was shown to be expressed during the invasion
of malignant melanomas (Airola et al, 1999). In addition, high
expression of MMP-1 was correlated with shorter disease-free
survival in metastatic melanoma (Nikkola et al, 2002). Moreover,
this enzyme can be activated by the plasminogen system (Benbow
et al, 1999). EDPs treatment triggered a high increase of the murine
counterpart of MMP-1, Mcol-A at the mRNA and at the protein
level. Moreover, we showed that the plasminogen system is actually
involved in the activation of Mcol-A, reinforcing our hypothesis.
The use of DQ-collagen permitted us to demonstrate that this
process triggers collagen degradation, explaining the influence of
EDPs on B16F1 invasion. The increase in Mcol-A secretion was
moreover demonstrated at the tissue level. Surprisingly, our
immunolabelling also suggest the presence of Mcol-A in the
nucleus. Such a colocalisation has also been reported for MIO-M1
cells, Tenon’s fibroblasts and ARPE cells. Such localisation is
thought to confer resistance to apoptosis and may explain the
well-known association of this enzyme with tumour cell survival
and spreading (Limb et al, 2005).
Our results strongly suggested that Mcol-A could be a key MMP
by which EDPs exhibit their effects on melanoma invasion. To
check this hypothesis, we used an anti-MMP-1 antibody directed
against the active site of human MMP-1 and previously used in
blocking experiments (Brennan et al, 2003). As the catalytic site
of Mcol-A possesses 63% homology with human MMP-1
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s(Balbin et al, 2001), we assumed that this antibody could be used
to block Mcol-A activity. As we hypothesised, the antibody
inhibited EDPs effect on B16F1 cell invasion with the same
efficiency than galardin, showing that Mcol-A is the key MMP
involved in EDP-induced melanoma invasion.
It has already been suggested that MMP-1 could be important in
melanoma development through its secretion by melanoma but also
by stromal cells (Woolley and Grafton, 1980; Airola et al, 1999) and,
recently, it was shown that shRNA-driven MMP-1 knockdown
inhibited metastasis formation in a xenograft model (Blackburn
et al, 2007). In our model, EDPs induced B16F1 invasion through
Mcol-A expression, reinforcing the fact that MMP-1 is a crucial
protease for melanoma invasion. However, its role in melanoma
invasion is not as documented as that of the MT1-MMP/MMP-2
system. Importantly, despite our in vitro results, we could not affirm
that Mcol-A production was limited to melanoma cells. Indeed,
some infiltrating and/or stromal cells could produce this MMP and
thereby participate to B16F1 invasion.
In conclusion, we propose that elastolysis could be a leading
phenomenon in melanoma invasion in vivo because it promotes
local collagenolysis. Previous in vitro studies suggesting that the
stromal reaction induced by EDPs could promote collagen
degradation through collagenase production (Brassart et al,
2001) supports this view. This could explain the histopathological
data underlining a strong correlation between elastin fragmenta-
tion and melanoma aggressiveness (Breslow, 1970; Feinmesser
et al, 2002). Moreover, it was proposed that EDPs could act as
factors promoting the transition between melanoma radial growth
phase to vertical growth phase in which melanoma cells infiltrate
and invade the dermis. Interestingly, this transition is associated
with a proteolytic switch in which MMP-1 expression is increased
(Hornebeck et al, 2005; Antonicelli et al, 2007). Our study
therefore reinforced this hypothesis.
It was suggested that partial preservation of elastic fibres in the
tumour depth was a relatively good predictive factor, whereas
complete absence of elastin was an adverse one (Feinmesser et al,
2002). However, this study was based on histological analyses and
no in vivo studies were carried out to confirm this hypothesis.
Consequently, owing to the lack of in vivo demonstration of the
active role of EDPs in melanoma growth, this point was under-
considered. Our results demonstrating that EDPs drastically
enhanced melanoma growth and invasion reinforced this assump-
tion. Consequently, we confirm and demonstrate that elastin
degradation could be an important predictive factor of melanoma
evolution.
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